TRxADE Q3 2022: revenue $2.4M (-6% YoY), gross margin 58%, net loss ($0.06)/share, adj EBITDA ($0.4M)

Scienture Holdings, Inc.

2022-Q3 EPS reported -$0.31 revenue$8,919,312

Revenue decreased 6% to $2.4M from $2.6M; gross margin improved to 58% from 50%.
Net loss narrowed to ($0.5M) or ($0.06) per share vs ($1.3M) or ($0.16) per share YoY.
Adjusted EBITDA turned negative at ($0.4M) compared to positive $0.7M in Q3 2021.
Added 291 new registered members in Q3; total ~14,100+; Bonum Health signed telemedicine deal with ShopRite.
Bonum Health entered distribution agreements with multiple insurance brokerage firms for employer groups in Oct 2022.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Scienture Holdings, Inc. reported for the three and nine months ended September 30, 2022 results: revenue $2.4 million, net income ($0.5) million, EPS ($0.06) per basic and diluted share.

Period: for the three and nine months ended September 30, 2022
Revenue: $2.4 million
Net income: ($0.5) million
EPS: ($0.06) per basic and diluted share
Result: reported results

Exact text from the filing

growth opportunities.” Third Quarter 2022 Financial Summary Consolidated revenues for the third quarter of 2022 compared to the third quarter of 2021, decreased 6% to $2.4 million, compared to $2.6 million, respectively. The consolidated decrease in revenue, is driven by decreases in revenue attributed to our TRxADE Prime and Community Specialty Pharmacy

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Scienture Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-030831

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.